Home
>
US Stocks
>
Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc (ALDX)

$10.37

+0.88

(+9.27%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Performance

  • $9.36
    $10.39
    $10.37
    downward going graph

    9.74%

    Downside

    Day's Volatility :9.91%

    Upside

    0.19%

    downward going graph
  • $2.86
    $10.89
    $10.37
    downward going graph

    72.42%

    Downside

    52 Weeks Volatility :73.74%

    Upside

    4.78%

    downward going graph

Returns

PeriodAldeyra Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
33.85%
0.7%
-6.8%
6 Months
54.06%
-8.3%
-6.0%
1 Year
222.79%
-1.9%
-4.6%
3 Years
87.92%
25.3%
25.9%

Highlights

Market Capitalization
545.1M
Book Value
$2.33
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.01
PEG Ratio
0.0
Wall Street Target Price
20.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-20.15%
Return On Equity TTM
-37.11%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-62.7M
Diluted Eps TTM
-1.01
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.41
EPS Estimate Next Year
-1.06
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.33

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Aldeyra Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 97.69%

Current $10.37
Target $20.50

Technicals Summary

Sell

Neutral

Buy

Aldeyra Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc
-5.85%
54.06%
222.79%
87.92%
17.16%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc
NA
NA
0.0
-1.41
-0.37
-0.2
0.0
2.33
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc
Buy
$545.1M
17.16%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • Perceptive Advisors LLC

    19.38%

  • Vanguard Group Inc

    4.27%

  • Knoll Capital Management LP

    3.33%

  • Eagle Asset Management, Inc.

    3.02%

  • Verition Fund Managegment, LLC

    2.67%

  • Dimensional Fund Advisors, Inc.

    1.92%

Corporate Announcements

  • Aldeyra Therapeutics Inc Earnings

    Aldeyra Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.

Organization
Aldeyra Therapeutics Inc
Employees
15
CEO
Dr. Todd C. Brady M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs